INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
INmune Bio published Phase 2 MINDFuL trial results for XPro in Alzheimer’s disease in the journal NPJ Dementia. In a pre-specified subgroup of 100 patients with amyloid positivity and inflammation biomarkers, XPro showed directional improvements across cognitive, functional, and biomarker endpoints over 24 weeks.
Key figures
- Drug Name
- XPro (XPro1595, pegipanermin)
- Phase Of Trial
- Phase 2
- Subgroup size
- 100
- Max effect size
- 0.27
- Trial duration weeks
- 24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.